MCID: LKM070
MIFTS: 53

Leukemia, Acute Monocytic

Categories: Blood diseases, Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leukemia, Acute Monocytic

MalaCards integrated aliases for Leukemia, Acute Monocytic:

Name: Leukemia, Acute Monocytic 57 36
Acute Monocytic Leukemia 11 75 28 53 5 14 16 71
Acute Monoblastic Leukemia and Acute Monocytic Leukemia 11
Acute Monocytic Leukaemia Without Mention of Remission 11
Acute Monocytic Leukemia Without Mention of Remission 11
M5b Acute Differentiated Monocytic Leukemia 71
Acute Monocytic Leukemia, Morphology 11
Acute Monocytic Leukemia, Fab M5 11
Leukemia, Monocytic, Acute 43
Acute Monocytic Leukaemia 11

Characteristics:


Inheritance:

Somatic mutation 57

Classifications:



External Ids:

Disease Ontology 11 DOID:8864
OMIM® 57 151380
ICD9CM 34 206.0
MeSH 43 D007948
SNOMED-CT 68 91859000
MedGen 40 C0023465
SNOMED-CT via HPO 69 22331004 413441006
UMLS 71 C0023465 C1318544

Summaries for Leukemia, Acute Monocytic

Disease Ontology: 11 A monocytic leukemia where the majority of monocytic cells are promonocytes.

MalaCards based summary: Leukemia, Acute Monocytic, also known as acute monocytic leukemia, is related to monocytic leukemia and leukemia. An important gene associated with Leukemia, Acute Monocytic is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Activation of NF-KappaB by PKR. The drugs Busulfan and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone marrow, and related phenotypes are acute monocytic leukemia and nervous system

Wikipedia: 75 Acute monocytic leukemia (AMoL, or AML-M5) is a type of acute myeloid leukemia. In AML-M5 >80% of the... more...

More information from OMIM: 151380

Related Diseases for Leukemia, Acute Monocytic

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Leukemia, Acute Monocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 monocytic leukemia 31.8 RARA KMT2A KAT6A IL1B EP300 CSF1
2 leukemia 31.5 U2AF1 RARA NUP98 MLLT10 KMT2A KAT6A
3 acute leukemia 31.3 NUP98 MPO MLLT10 KMT2A CSF1 CREBBP
4 acute myelomonocytic leukemia 31.0 MPO KMT2A CSF1 CREBBP
5 aleukemic leukemia cutis 30.9 RARA MPO
6 myeloid sarcoma 30.8 U2AF1 MPO KMT2A
7 langerhans cell histiocytosis 30.8 U2AF1 CSF1 CD40
8 chronic myelomonocytic leukemia 30.7 U2AF1 MPO H2AC18 CSF1
9 exanthem 30.7 MPO IL1B H2AC18
10 b-lymphoblastic leukemia/lymphoma 30.6 U2AF1 MPO KMT2A
11 juvenile myelomonocytic leukemia 30.5 U2AF1 RARA NUP98 KMT2A
12 aplastic anemia 30.5 U2AF1 MPO IL1B H2AC18 CSF1
13 leukemia, acute lymphoblastic 30.5 U2AF1 MPO MLLT10 MIR155 KMT2A H2AC18
14 pancytopenia 30.4 U2AF1 MPO KMT2A H2AC18 CSF1
15 precursor t-cell acute lymphoblastic leukemia 30.4 NUP98 MPO MLLT10 KMT2A
16 myeloid leukemia 30.4 U2AF1 RARA NUP98 MPO MLLT10 KMT2A
17 acute megakaryocytic leukemia 30.4 U2AF1 NUP98 MPO KMT2A
18 myeloproliferative neoplasm 30.4 U2AF1 THBD MPO MIR155 KMT2A H2AC18
19 leukemia, acute myeloid 30.3 U2AF1 RARA NUP98 MPO MLLT10 MIR155
20 myelofibrosis 30.3 U2AF1 THBD MPO IL1B
21 respiratory failure 30.3 THBD MPO MIR155 IL1B H2AC18
22 childhood acute myeloid leukemia 30.3 U2AF1 RARA NUP98 MLLT10 KMT2A
23 essential thrombocythemia 30.2 U2AF1 THBD H2AC18 CD14
24 hematologic cancer 30.2 U2AF1 RARA NUP98 MLLT10 MIRLET7A1 MIR155
25 adult respiratory distress syndrome 30.2 THBD MPO IL1B H2AC18
26 leukemia, chronic lymphocytic 30.2 U2AF1 MIR155 KMT2A H2AC18 CD40
27 peripheral t-cell lymphoma 30.2 NME1 MIR155 H2AC18
28 childhood leukemia 30.1 U2AF1 RARA NUP98 MLLT10 KMT2A H2AC18
29 leukemia, chronic myeloid 30.1 U2AF1 RARA NUP98 NME1 MPO MIRLET7A1
30 myelodysplastic syndrome 30.1 U2AF1 RARA NUP98 MPO KMT2A KAT6A
31 behcet syndrome 30.1 THBD MPO IL1B H2AC18 CD40
32 central nervous system disease 30.1 U2AF1 MIRLET7A1 MIR155 H2AC18
33 lymphoma, non-hodgkin, familial 30.1 U2AF1 MIR155 KMT2A H2AC18 CD40
34 myeloma, multiple 30.0 U2AF1 MIR155 MALAT1 IL1B H2AC18 CSF1
35 acute promyelocytic leukemia 29.7 U2AF1 THBD RARA NUP98 MPO KMT2A
36 nervous system disease 29.3 U2AF1 MPO MIRLET7F1 MIRLET7A1 MIR155 IL1B
37 acute monoblastic leukemia 11.8
38 adult acute monocytic leukemia 11.8
39 acute monoblastic/monocytic leukemia 10.8
40 acute myeloid leukemia with recurrent genetic anomaly 10.7
41 acute myeloid leukemia with t(8;16)(p11;p13) translocation 10.5 KAT6A CREBBP
42 acute megakaryoblastic leukemia without down syndrome 10.4 NUP98 KMT2A
43 menke-hennekam syndrome 10.4 EP300 CREBBP
44 neonatal leukemia 10.4 KMT2A KAT6A CREBBP
45 childhood acute megakaryoblastic leukemia 10.4 NUP98 KMT2A
46 autosomal dominant intellectual developmental disorder 31 10.4 KAT6A EP300 CREBBP
47 rare genetic intellectual disability 10.4 KMT2A EP300 CREBBP
48 rubinstein-taybi syndrome 1 10.4 EP300 CREBBP
49 mixed phenotype acute leukemia, t/myeloid 10.4 MLLT10 KMT2A
50 cornelia de lange syndrome 2 10.3 EP300 CREBBP

Graphical network of the top 20 diseases related to Leukemia, Acute Monocytic:



Diseases related to Leukemia, Acute Monocytic

Symptoms & Phenotypes for Leukemia, Acute Monocytic

Human phenotypes related to Leukemia, Acute Monocytic:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 acute monocytic leukemia 30 HP:0004845

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Hematology:
acute monocytic leukemia

Clinical features from OMIM®:

151380 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Leukemia, Acute Monocytic:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.21 CD40 CREBBP CSF1 EP300 IL1B KAT6A
2 immune system MP:0005387 10.16 CD14 CD40 CREBBP CSF1 EP300 IL1B
3 normal MP:0002873 10.11 CD40 CREBBP EP300 KAT6A KMT2A MALAT1
4 cardiovascular system MP:0005385 10.06 CREBBP CSF1 EP300 IL1B KAT6A KMT2A
5 hematopoietic system MP:0005397 10.03 CD14 CD40 CREBBP CSF1 EP300 IL1B
6 neoplasm MP:0002006 10.02 CREBBP EP300 IL1B KMT2A NME1 RARA
7 liver/biliary system MP:0005370 10.01 CREBBP CSF1 KAT6A KMT2A MLLT10 NME1
8 craniofacial MP:0005382 9.97 CREBBP CSF1 EP300 IL1B KAT6A KMT2A
9 mortality/aging MP:0010768 9.8 CD14 CREBBP CSF1 EP300 IL1B KAT6A
10 integument MP:0010771 9.28 CREBBP CSF1 IL1B KAT6A KMT2A MLLT10

Drugs & Therapeutics for Leukemia, Acute Monocytic

Drugs for Leukemia, Acute Monocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3 55-98-1 2478
2
Aldesleukin Approved Phase 3 110942-02-4
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
7
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
8
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 2826718
9
Fludarabine Approved Phase 3 75607-67-9, 21679-14-1 30751 657237
10
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
11
Tioguanine Approved Phase 3 154-42-7 2723601
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
14
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
15
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
17
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
18
Daunorubicin Approved Phase 3 20830-81-3 30323
19
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
22
Tipifarnib Investigational Phase 3 192185-72-1 159324
23 Alkylating Agents Phase 3
24 Antineoplastic Agents, Alkylating Phase 3
25 Anti-Retroviral Agents Phase 3
26 Interleukin-2 Phase 3
27 Anti-HIV Agents Phase 3
28 Analgesics, Non-Narcotic Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 Hormone Antagonists Phase 3
31 Antiemetics Phase 3
32 Anti-Inflammatory Agents Phase 3
33 glucocorticoids Phase 3
34 Gastrointestinal Agents Phase 3
35 Folic Acid Antagonists Phase 3
36 Folate Phase 3
37 Vitamin B9 Phase 3
38 Vitamin B Complex Phase 3
39 Cytochrome P-450 Enzyme Inhibitors Phase 3
40 N-Methylaspartate Phase 3
41 BB 1101 Phase 3
42 Hydrocortisone-17-butyrate Phase 3
43 Hydrocortisone 17-butyrate 21-propionate Phase 3
44
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
45
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
46
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
47
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
48
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
49
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
50
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
2 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
3 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
4 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
5 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
6 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
7 Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children: A Prospective Multicenter Study in South China Recruiting NCT05313958 Phase 2, Phase 3 Cladribine;G-CSF;Cytarabine;Idarubicin;Mitoxantrone;Sorafenib
8 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
9 A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
10 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
11 A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
12 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
13 Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, Previously Untreated, Poor Risk Acute Myelogenous Leukemias (AML) Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
14 A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies Completed NCT00462605 Phase 2 entinostat;sargramostim
15 A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML) Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
16 Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
17 A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
18 A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent Completed NCT02019069 Phase 2 liposomal cytarabine-daunorubicin CPX-351
19 Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
20 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
21 Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older Completed NCT00093418 Phase 2 tipifarnib
22 PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
23 A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML) Completed NCT00602771 Phase 2 tipifarnib;etoposide
24 A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy Completed NCT00352365 Phase 2 lenalidomide
25 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML) Completed NCT00305773 Phase 2 vorinostat
26 A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML) Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
27 Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission Completed NCT00045435 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
28 Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML Completed NCT01235572 Phase 2
29 A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
30 Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Completed NCT01361464 Phase 2 Tipifarnib
31 Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML Completed NCT01168219 Phase 2 Azacitidine;Busulfan;Fludarabine Phosphate;Methotrexate;Tacrolimus
32 Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. "7+3" for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML) Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
33 A Multicenter, Randomized, Controlled Clinical Trial of Venetoclax, Azacytidine Combined With Chidamide for the Treatment of Newly Diagnosed Acute Monocytic Leukemia Patients That Are Ineligible for Intensive Chemotherapy Recruiting NCT05566054 Phase 2 Chidamide;Azacitidine;Venetoclax
34 A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia Active, not recruiting NCT00658814 Phase 2 Azacitidine;Gemtuzumab Ozogamicin
35 A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy Active, not recruiting NCT02071901 Phase 2 eltrombopag olamine
36 Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML) Active, not recruiting NCT01627041 Phase 2 Cytarabine;Daunorubicin Hydrochloride;Decitabine
37 Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia Terminated NCT00096148 Phase 2 idarubicin;cytarabine
38 Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia Terminated NCT00673153 Phase 2 gemtuzumab ozogamicin;vorinostat
39 OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age Terminated NCT02029417 Phase 2 cytarabine;omacetaxine mepesuccinate;decitabine
40 A Phase 2 Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia With Mutated Nucleophosmin-1 Terminated NCT02030405 Phase 2 Ixazomib
41 Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML. Terminated NCT01607645 Phase 2 decitabine;idarubicin;cytarabine
42 A Phase 2 Study of EMD 121974 as Maintenance Therapy for Patinets With Acute Myeloid Leukemia in Complete Remission Terminated NCT00089388 Phase 2 cilengitide
43 Vitamin D3 Supplementation in Acute Myeloid Leukemia: Pharmacokinetic Study Terminated NCT01521936 Phase 2
44 Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study Terminated NCT01342887 Phase 1, Phase 2 cyclosporine;pravastatin sodium;mitoxantrone hydrochloride;etoposide
45 A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene Withdrawn NCT01835288 Phase 2 arsenic trioxide
46 Phase II Study of Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia in First Remission Withdrawn NCT00101140 Phase 2 anti-thymocyte globulin;fludarabine phosphate;thiotepa
47 Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia Completed NCT00101296 Phase 1 tipifarnib
48 Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML) Completed NCT01839240 Phase 1 azacitidine;cytarabine;mitoxantrone hydrochloride
49 Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias Completed NCT00470197 Phase 1 alvocidib;cytarabine;mitoxantrone hydrochloride
50 A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias Completed NCT00383474 Phase 1 Bortezomib;Tipifarnib

Search NIH Clinical Center for Leukemia, Acute Monocytic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Monocytic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Acute Monocytic:
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Monocytic:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: leukemia, monocytic, acute

Genetic Tests for Leukemia, Acute Monocytic

Genetic tests related to Leukemia, Acute Monocytic:

# Genetic test Affiliating Genes
1 Acute Monocytic Leukemia 28

Anatomical Context for Leukemia, Acute Monocytic

Organs/tissues related to Leukemia, Acute Monocytic:

MalaCards : Monocytes, Myeloid, Bone Marrow, Bone, Endothelial, T Cells, Skin

Publications for Leukemia, Acute Monocytic

Articles related to Leukemia, Acute Monocytic:

(show top 50) (show all 1134)
# Title Authors PMID Year
1
Familial monocytic leukaemia. A report of two families. 57
295149 1979
2
The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22. 53 62
15897884 2005
3
Is t(10;11)(p11.2;q23) involving MLL and ABI-1 genes associated with congenital acute monocytic leukemia? 53 62
12547160 2002
4
Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b). 53 62
11530805 2001
5
Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. 53 62
11243405 2001
6
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). 53 62
10824998 2000
7
[In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia]. 53 62
10897214 2000
8
Acute monocytic leukemia with a novel 10;11 rearrangement resolved by fluorescence in situ hybridization. 53 62
10731585 2000
9
Molecular analysis of the rearranged genome and chimeric mRNAs caused by the t(6;11)(q27;q23) chromosome translocation involving MLL in an infant acute monocytic leukemia. 53 62
10719372 2000
10
Involvement of the MLL and RARalpha genes in a patient with acute monocytic leukemia with t(11;17)(q23;q12) 53 62
10720155 2000
11
Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. 53 62
9731070 1998
12
Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies. 53 62
9490665 1998
13
Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kappaB. 53 62
9464836 1997
14
[Detection of MLL gene rearrangement in acute myelomonocytic and monocytic leukemia]. 53 62
10743082 1997
15
Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia. 53 62
8896423 1996
16
Successful treatment of a 93-year-old patient with hypoplastic acute monocytic leukemia using macrophage colony-stimulating factor. 53 62
7758063 1995
17
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. 53 62
7949133 1994
18
A case of acute monocytic leukemia with t(11;17) involving a rearrangement of MLL-1 and a region proximal to the RARA gene. 53 62
8194047 1994
19
[Molecular diagnosis of leukemia and lymphoma]. 53 62
8176845 1994
20
Molecular characterization of the gene for human interleukin-1 beta converting enzyme (IL1BC). 53 62
8034320 1994
21
MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. 53 62
8414510 1993
22
A novel translocation, t(9;11)(q33;q23) involving the HRX gene in an acute monocytic leukemia. 53 62
8019892 1993
23
Cytotoxic and Pro-Apoptotic Effects of Leaves Extract of Antiaris africana Engler (Moraceae). 62
36431822 2022
24
Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells. 62
36430734 2022
25
A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia. 62
35978554 2022
26
M2 macrophage-conditioned medium inhibits intervertebral disc degeneration in a tumor necrosis factor-α-rich environment. 62
35170802 2022
27
17β-neriifolin from unripe fruits of Cerbera manghas suppressed cell proliferation via the inhibition of HOXA9-dependent transcription and the induction of apoptosis in the human AML cell line THP-1. 62
36266527 2022
28
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo. 62
35795096 2022
29
A case of peripheral T-cell lymphoma, NOS, mimicking acute monocytic leukemia. 62
35064930 2022
30
Correction to: Prioritizing risk genes as novel stratification biomarkers for acute monocytic leukemia by integrative analysis. 62
36156166 2022
31
Post-cardiac Arrest Leukocytosis Mimicking Acute Monocytic Leukemia. 62
36299948 2022
32
[Effect of polydatin on the proliferation and apoptosis of THP-1 cells and the mechanism]. 62
35894200 2022
33
PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch. 62
35467057 2022
34
Non-Hodgkin lymphoma mimicking acute leukemia: a report of six cases and review of the literature. 62
35496359 2022
35
Chromosomal Translocations Detection in Cancer Cells Using Chromosomal Conformation Capture Data. 62
35885953 2022
36
Prioritizing risk genes as novel stratification biomarkers for acute monocytic leukemia by integrative analysis. 62
35771283 2022
37
Solvent effects on the crystallization and structure of ternary copper(ii) coordination compounds with l-threonine and 1,10-phenanthroline. 62
35694423 2022
38
A novel bicyclic lactone and other polyphenols from the commercially important vegetable Anthriscus cerefolium. 62
35551255 2022
39
Homocysteine Suppresses Autophagy Through AMPK-mTOR-TFEB Signaling in Human THP-1 Macrophages. 62
35121714 2022
40
Retraction. 62
35297049 2022
41
Therapy-Related Acute Myeloid Leukemia Mimicking Lymphoma: a Diagnostic Dilemma. 62
35536071 2022
42
Infiltrative Chorioretinopathy in Recurrent Acute Monocytic Leukemia. 62
35525577 2022
43
Subtype discrimination of acute myeloid leukemia based on plasma SERS technique. 62
35063821 2022
44
Optimized flow cytometric detection of transient receptor potential vanilloid-1 (TRPV1) in human hematological malignancies. 62
35477804 2022
45
Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy. 62
35133573 2022
46
FNF-12, a novel benzylidene-chromanone derivative, attenuates inflammatory response in in vitro and in vivo asthma models mediated by M2-related Th2 cytokines via MAPK and NF-kB signaling. 62
34468975 2022
47
Dexamethasone Sensitizes Acute Monocytic Leukemia Cells to Ara-C by Upregulating FKBP51. 62
35860568 2022
48
Gingival Infiltration in Acute Monocytic Leukemia. 62
34986288 2022
49
Integrative analysis of macrophage ribo-Seq and RNA-Seq data define glucocorticoid receptor regulated inflammatory response genes into distinct regulatory classes. 62
36284713 2022
50
The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients. 62
34996458 2022

Variations for Leukemia, Acute Monocytic

ClinVar genetic disease variations for Leukemia, Acute Monocytic:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NF1 NM_001042492.3(NF1):c.2747A>G (p.Asn916Ser) SNV Uncertain Significance
229977 rs765043916 GRCh37: 17:29556380-29556380
GRCh38: 17:31229362-31229362

Copy number variations for Leukemia, Acute Monocytic from CNVD:

6 (show all 23)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21832 1 16200000 20400000 Gain Acute monocytic leukemia
2 31525 1 28000000 30200000 Gain Acute monocytic leukemia
3 61776 12 10100000 12800000 Loss Acute monocytic leukemia
4 90243 15 20700000 25700000 Gain Acute monocytic leukemia
5 93369 15 52900000 59100000 Gain Acute monocytic leukemia
6 108855 17 23200000 28800000 Deletion NF1 Acute monocytic leukemia
7 110292 17 31800000 38100000 Gain Acute monocytic leukemia
8 116498 17 67100000 70900000 Loss Acute monocytic leukemia
9 125458 19 13900000 20000000 Gain Acute monocytic leukemia
10 133734 19 6900000 13900000 Gain Acute monocytic leukemia
11 140901 2 203300000 204900000 Loss Acute monocytic leukemia
12 188152 4 59500000 66600000 Loss Acute monocytic leukemia
13 190404 4 88000000 93700000 Loss Acute monocytic leukemia
14 191655 5 1 4500000 Gain Acute monocytic leukemia
15 196530 5 168500000 172800000 Gain Acute monocytic leukemia
16 201329 5 68400000 73300000 Gain Acute monocytic leukemia
17 206333 6 139000000 142800000 Loss Acute monocytic leukemia
18 219029 7 121100000 123800000 Loss Acute monocytic leukemia
19 224721 7 37200000 43300000 Loss Acute monocytic leukemia
20 226783 7 61700000 67000000 Loss Acute monocytic leukemia
21 226785 7 61700000 77500000 Loss Acute monocytic leukemia
22 243519 8 84600000 86900000 Gain Acute monocytic leukemia
23 250024 9 19900000 25600000 Loss Acute monocytic leukemia

Expression for Leukemia, Acute Monocytic

Search GEO for disease gene expression data for Leukemia, Acute Monocytic.

Pathways for Leukemia, Acute Monocytic

Pathways related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 MIR155 IL1B EP300 CREBBP CD40 CD14
2
Show member pathways
11.45 IL1B EP300 CREBBP
3
Show member pathways
11.34 RARA EP300 CREBBP
4 11.23 KAT6A EP300 CREBBP
5 11.13 THBD IL1B CSF1 CD14
6 10.61 NME1 EP300
7 10 MPO IL1B CSF1

GO Terms for Leukemia, Acute Monocytic

Cellular components related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone acetyltransferase complex GO:0000123 9.02 KAT6A EP300 CREBBP

Biological processes related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-templated transcription GO:0045893 10.1 RARA NUP98 KMT2A KAT6A IL1B EP300
2 N-terminal peptidyl-lysine acetylation GO:0018076 9.46 EP300 CREBBP
3 protein acetylation GO:0006473 9.43 KAT6A EP300 CREBBP
4 response to lipopolysaccharide GO:0032496 9.28 THBD MPO IL1B CSF1 CD14

Molecular functions related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 10.03 CREBBP EP300 KMT2A MLLT10 MPO RARA
2 transcription coactivator binding GO:0001223 9.8 RARA EP300 CREBBP
3 peptide-lysine-N-acetyltransferase activity GO:0061733 9.71 EP300 CREBBP
4 histone acetyltransferase activity GO:0004402 9.63 KAT6A EP300 CREBBP
5 histone H3 acetyltransferase activity GO:0010484 9.54 KAT6A EP300
6 acetyltransferase activity GO:0016407 9.43 KAT6A EP300 CREBBP
7 peptide N-acetyltransferase activity GO:0034212 8.92 EP300 CREBBP

Sources for Leukemia, Acute Monocytic

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....